Punitha Rathnam, MD
Psychiatry · Goldsboro, NCNPI 1558564005
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,795 of the $7,638 with a category attached, or 89.0%. 28 manufacturers reported payments, led by AbbVie at 25.2% of the total. 2025 is the largest year on record at $1,905, 2.4 times the $811 reported in 2019. Among psychiatry clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 464 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Brainsway USA Inc$705
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$603
- Teva Pharmaceuticals USA, Inc.$561
- Vanda Pharmaceuticals Inc.$491
- plus $2K from 22 others
Across 99 payments — averaging $5885.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$287K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$175K
- Alkermes, Inc.$75K
- Vanda Pharmaceuticals Inc.$46K
What the payments were for
- Travel & lodging$7059%
- Food & beverage$6,79589%
- Education$1392%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 154 | $1,924 |
| Otsuka America Pharmaceutical, Inc. | 68 | $1,112 |
| Brainsway USA Inc | 1 | $705 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 35 | $603 |
| Teva Pharmaceuticals USA, Inc. | 32 | $561 |
| Vanda Pharmaceuticals Inc. | 33 | $491 |
| Alkermes, Inc. | 32 | $459 |
| Johnson & Johnson | 26 | $407 |
| Neurocrine Biosciences, Inc. | 16 | $269 |
| Supernus Pharmaceuticals, Inc. | 16 | $258 |
| Lundbeck LLC | 10 | $178 |
| Corium, LLC | 7 | $105 |
| Tris Pharma Inc | 5 | $88 |
| Ironshore Pharmaceuticals Inc. | 5 | $83 |
| E.r. Squibb & Sons, L.L.C. | 3 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $62 |
| Sunovion Pharmaceuticals Inc. | 2 | $46 |
| Shire North American Group Inc | 2 | $30 |
| Eisai Inc. | 2 | $28 |
| Neos Therapeutics, LP | 2 | $27 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $26 |
| Almatica Pharma LLC | 1 | $18 |
| Luye Pharma (USA) Ltd. | 1 | $17 |
| OWP Pharmaceuticals, Inc. | 1 | $16 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| Noven Therapeutics, LLC | 1 | $13 |
| Novo Nordisk | 1 | $13 |
| Vertical Pharmaceuticals, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- deep tms$705
How this compares
$7,638 in reported general payments places this provider in the 90th percentile of 1,108 psychiatry providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 58 | $89,838 |
| Invega SustennaPaliperidone Palmitate | 19 | $53,476 |
| Aripiprazole | 140 | $8,608 |
| VyvanseLisdexamfetamine Dimesylate | 17 | $6,876 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,592 |
| CombiganBrimonidine Tartrate/Timolol | 23 | $4,930 |
| Hydroxyzine Hcl | 113 | $3,498 |
| Benztropine Mesylate | 229 | $3,089 |
| Quetiapine Fumarate | 160 | $2,996 |
| LumiganBimatoprost | 11 | $2,880 |
| Lurasidone Hcl | 75 | $2,683 |
| Ziprasidone Hcl | 57 | $2,622 |
| Lisdexamfetamine Dimesylate | 13 | $2,484 |
| Buspirone Hcl | 160 | $2,272 |
| Clomipramine Hcl | 21 | $2,109 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Combigan, Lumigan | $1,924 | $97,64892 claims |
| Johnson & JohnsonInvega Sustenna | $407 | $53,47619 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $62 | $12,46729 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,108 psychiatry providers in North Carolina.
Other psychiatry in Goldsboro
- Meredith GodwinGoldsboro$21K
- Craig ChepkeHuntersville$4.1M
- Mark ReynoldsDurham$3.2M
- James BarkerHickory$2.1M
- Brian FarahWinston Salem$605K
- Krishna TalluriMorrisville$591K
- Ramesh GihwalaGastonia$545K
- Keshavpal ReddyGreensboro$480K
- Robert MilletRaleigh$476K
- Steven SzaboDurham$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.